$15.81
-5.50%Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
Quality against peers; 50 is the peer median.
No reported financials for this company yet: it has too few SEC filings to chart.
The next report, and the record against analysts' estimates.
IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.
The companies closest in size in Biotechnology (filled from its sector when there are few), with the median and rank across all 580 in the industry.